GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] TRIUMPH is doing more work than we give it credit for — 56 comments in the full submission. View in context.
2k
c/trialwatch·submitted 1 year ago by u/paper_trail_paula

[Discussion] TRIUMPH is doing more work than we give it credit for

Discussionbranch of 7 comments

TRIUMPH is doing more work than we give it credit for. Making the case below, and I expect to lose some of it in the comments. Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point. The discontinuation numbers were the most useful thing in the paper for me…

Read the full submission and all 56 comments →

This branch

7 comments, started 1 year ago
u/week_four_wall145 points·1 year ago

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

replysharereportpermalink
u/aurel_mwangi118 points·1 year ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/paper_trail_paulaOPvetting68 points·1 year ago

registry entry, protocol, publication — three different documents

replysharereportpermalink
[removed]83 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/adaeze_weiss112 points·1 year ago

the confidence interval is the finding, the point estimate is the headline

replysharereportpermalink
u/paper_trail_paulaOPvetting79 points·1 year ago

discontinuation rate is a result, not a footnote

replysharereportpermalink
u/nightowl_injector53 points·1 year ago·edited

intention to treat versus completers changes the number substantially

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →